Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing

Executive Summary

Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8
Advertisement

Related Content

Medicare Rx Benefit Will Be Implemented By New CMS Team; Scully Resigns
Medicare Rx Benefit Will Be Implemented By New CMS Team; Scully Resigns
Medicare Rx Benefit Costs Will Exceed $400 Bil. – Rep. Waxman
Medicare Rx Benefit Costs Will Exceed $400 Bil. – Rep. Waxman
Reimportation Survey Demonstrates Rx Industry’s Public Relations Challenge
Reimportation Survey Demonstrates Rx Industry’s Public Relations Challenge
Nexium-Style Products Encourage Price Competition, FDA’s McClellan Says
AstraZeneca Retains 90% Of GI Business Despite Prilosec Generics
Nexium Prescribers Should Be “Embarrassed,” CMS’ Scully Tells AMA
Nexium Prescribers Should Be “Embarrassed,” CMS’ Scully Tells AMA
Advertisement
UsernamePublicRestriction

Register

PS042620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel